DMARD use in rheumatoid arthritis: can we predict treatment response?
View/ Open
Date
2015-06Author
Genga, EK
Moots, RJ
Oyoo, GO
Language
enMetadata
Show full item recordAbstract
Objective: To review the current and
emerging predictors of treatment response
by DMARDS in Rheumatoid Arthritis
(RA) patients.
Data source: Published original research
work and reviews were searched in
English related to determinants of
treatment response in rheumatoid arthritis
on DMARDS
Study design: Only articles that emphasis
on determinants of rheumatoid arthritis
treatment response with DMARDS
Data extraction: Online and library
searches done.
Data synthesis: Data added and summarized
Conclusions: Treatment of RA has
been based on the use of a group of
Disease-Modifying Antirheumatic Drugs
(DMARDs), of which methotrexate
is the most widely used. Although
comprehensive clinical experience exists
for MTX and synthetic DMARDs, to date it
has not been possible to preview correctly
whether or not a patient will respond to
treatment with these drugs. Predicting
response to MTX and other DMARDs
would allow the selection of patients
based on their likelihood of response,
thus enabling individualized therapy and
avoiding unnecessary adverse effects and
elevated costs. Distinguishing responders
from non-responders at treatment start
as studies have failed to consistently
reproduce similar determinants. Variables
possibly influencing drug effectiveness
may be related to disease, patient,
treatment, clinical or biological (genetic
and non-genetic) factors. This study
seeks to review the current data regarding
biomarkers of treatment response to
DMARDS.
Citation
Genga, EK., Moots, RJ and Oyoo GO (2015). DMARD use in rheumatoid arthritis: can we predict treatment response?. Afr J Rheumatol; 3(2): 50-58Publisher
University of Nairobi
Collections
- Faculty of Health Sciences (FHS) [10387]